Abstract
Amyloid-β peptide (Aβ) seems to have a central role in the neuropathology of Alzheimer's disease (AD)1. Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes2,3. Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (Aβ42)4,5,6,7,8, which is the predominant form found in the amyloid plaques of Alzheimer's disease9,10. The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner11,12. In the present study, transgenic animals were immunized with Aβ42, either before the onset of AD-type neuropathologies (at 6 weeks of age) or at an older age (11 months), when amyloid-β deposition and several of the subsequent neuropathological changes were well established. We report that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-β may be effective in preventing and treating Alzheimer's disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Role of neuroinflammation in neurodegeneration development
Signal Transduction and Targeted Therapy Open Access 12 July 2023
-
A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice
Alzheimer's Research & Therapy Open Access 14 January 2023
-
Virus-like particle vaccinology, from bench to bedside
Cellular & Molecular Immunology Open Access 12 August 2022
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hyman, B. T. New neuropathological criteria for Alzheimer disease. Arch. Neurol. 55, 1174–1176 (1998).
Tanzi, R. E. et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3, 159–168 (1996).
Hardy, J. New insights into the genetics of Alzheimer's disease. Ann. Med. 28, 255–258 (1996).
Citron, M. et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672–674 (1992).
Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864–870 (1996).
Suzuki, N. et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β APP717) mutants. Science 264, 1336–1340 (1994).
Citron, M. et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nature Med. 3, 67–72 (1997).
Borchelt, D. R. et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005–1013 (1996).
Iwatsubo, T. et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 45–53 (1994).
Lippa, C. F., Nee, L. E., Mori, H. refau>& St George-Hyslop, P. Aβ-42 deposition precedes other changes in PS-1 Alzheimer's disease. Lancet 352, 1117–1118 (1998).
Games, D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523–527 (1995).
Johnson-Wood, K. et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 1550–1555 (1997).
Liang, J. S. et al. Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci. Lett. 225, 73–76 (1997).
McGeer, E. G. refau>& McGeer, P. L. The role of the immune system in neurodegenerative disorders. Mov. Disorders 12, 855–858 (1997).
Seubert, P. et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325–327 (1992).
Seubert, P. et al. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide. Nature 361, 260–263 (1993).
Acknowledgements
We thank Rae Lyn Burke for helpful comments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schenk, D., Barbour, R., Dunn, W. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999). https://doi.org/10.1038/22124
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/22124
This article is cited by
-
Role of neuroinflammation in neurodegeneration development
Signal Transduction and Targeted Therapy (2023)
-
Clinical relevance of animal models in aging-related dementia research
Nature Aging (2023)
-
A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice
Alzheimer's Research & Therapy (2023)
-
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Current Treatment Options in Neurology (2023)
-
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Translational Neurodegeneration (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
